Playing it safe in science can cause lasting harm: academy president
21 May, 2004 by Graeme O'NeillThe President of the Australian Academy of Science, Dr Jim Peacock, has warned that governments could do “irreparable and lasting harm” by seeking to play safe when confronted by controversial technological change.
AustCancer snaps up US vaccine developer
21 May, 2004 by Melissa TrudingerAustralian Cancer Technologies (AustCancer, ASX: ACU) is the latest Australian company to announce an acquisition of a US company, with its proposal to acquire US vaccine developer Galenica Pharmaceuticals for around US$5 million in shares.
The GM ban: what it will mean for plant biotech
20 May, 2004 by Graeme O'NeillThe future of the Victorian wheat industry has moved from a biosecure glasshouse into a small, netted field plot at the International Centre for Cereal Breeding (CIMMYT) in Mexico.
Political science: behind the GM ban
20 May, 2004 by Graeme O'NeillAlmost two months ago, the Victorian Labor government stunned the state's biotechnology industry by imposing a four-year, legislated moratorium on genetically modified (GM) canola cropping.
Living Cell Technologies issues prospectus for $7 million ASX listing
20 May, 2004 by Melissa TrudingerCell therapeutics company Living Cell Technologies has issued a prospectus to raise almost AUD$7 million through both a rights issue and a general issue.
Independent trial affirms potential of Chemeq’s antimicrobial
20 May, 2004 by Graeme O'NeillAn independent trial of the polymeric antimicrobial developed by Perth pharmaceutical company Chemeq (ASX:CMQ) has confirmed the drug’s potential to improve disease control in the poultry industry, while transforming its knife-edge economics.
Regenera to list in early June
19 May, 2004 by Renate KrelleThe CEO of Perth-based biotech Regenera, Tony Fitzgerald, said today that he expected the company’s offer to close next week, oversubscribed, ready for a June listing.
Anadis to supply nutraceutical to Chinese military
19 May, 2004 by Graeme O'NeillMelbourne biotech Anadis Limited (ASX:ANX) has announced the first sale to China of its bovine colostrum-based nutraceutical – a 3-tonne consignment destined to be used as a health food by the Chinese military and other agencies, to build immunity to enteric diseases.
New BIF funding up for grabs
17 May, 2004 by Renate KrelleAn undisclosed amount of new funding will be made available under the sixth round of the federal Biotechnology Innovation Fund (BIF), newly rebadged as part of the $1 billion, five-year Commercial Ready program.
Dynamic Hearing licenses software to Germany’s Interton
17 May, 2004 by Melissa TrudingerHearing aid software developer Dynamic Hearing has entered into a licensing agreement with German hearing aid manufacturer Interton Hoergeraete.
Cryptome lures expat home for advisory role
14 May, 2004 by Renate KrelleMelbourne-based proteomics researcher Cryptome Pharmaceuticals has lured Dr Paul Cossum, an Australian who for the last 20 years has worked in American biopharmas, to join the company. As a scientific consultant, Cossum will provide advice on drug development and regulatory affairs.
PanBio to raise $7 million to speed products to market
13 May, 2004 by Melissa TrudingerDiagnostics company Panbio (ASX: PBO) has raised AUD$3 million in a placement to existing and new shareholders at a price of $0.42 per share, and plans to raise a further $4.2 million through a share purchase plan to existing shareholders at the same price.
Monsanto drops Australian GM canola program
12 May, 2004 by Graeme O'NeillMonsanto Australia will make no further investment in efforts to commercialise its genetically modified (GM) herbicide-tolerant Roundup Ready canola in Australia for at least 12 months.
VRI launches probiotics into pharmacies
12 May, 2004 by Renate KrelleVRI BioMedical announced today that its probiotics range for the treatment of irritable bowel syndrome, diarrhoea and general intestinal health, is due to hit pharmacy shelves.
Novogen to begin trials with phenoxodiol-derivative
12 May, 2004 by Melissa TrudingerNovogen (ASX: NRT) has been approved to commence a Phase I clinical trial at Sydney's St George Hospital of its second anti-cancer drug NV-18, a derivative of the company's first generation drug phenoxodiol.
